Background: YKL-40 is a chitinase-like protein present in serum of healthy subjects and its levels are increased in several human inflammatory diseases. The aim of this study was to evaluate the levels of both serum and sputum YKL-40 in cystic fibrosis (CF) patients. Methods: Serum and sputum YKL-40 levels were measured in a cohort of twenty-eight patients with a diagnosis of CF and twenty healthy controls. Results: Serum YKL-40 levels were significantly higher in CF patients (88.8 ± 56.7 vs 18.6 ± 2.9 ng/ml, P b 0.001), as well as sputum YKL-40 levels (138.5 ± 132.7 vs 28.2 ± 24.34, P b 0.001) than in healthy controls. Serum YKL-40 levels were closely related to YKL-40 levels assessed in sputum samples (r = 0.71; P b 0.01). Conclusions: YKL-40 is elevated in CF patients and is further elevated during severe exacerbations. Longitudinal studies in infant are needed to establish its role in disease pathogenesis.

YKL-40 as marker of severe lung disease in cystic fibrosis patients

Manti, Sara;Cuppari, Caterina;Salpietro, Carmelo
Ultimo
2016-01-01

Abstract

Background: YKL-40 is a chitinase-like protein present in serum of healthy subjects and its levels are increased in several human inflammatory diseases. The aim of this study was to evaluate the levels of both serum and sputum YKL-40 in cystic fibrosis (CF) patients. Methods: Serum and sputum YKL-40 levels were measured in a cohort of twenty-eight patients with a diagnosis of CF and twenty healthy controls. Results: Serum YKL-40 levels were significantly higher in CF patients (88.8 ± 56.7 vs 18.6 ± 2.9 ng/ml, P b 0.001), as well as sputum YKL-40 levels (138.5 ± 132.7 vs 28.2 ± 24.34, P b 0.001) than in healthy controls. Serum YKL-40 levels were closely related to YKL-40 levels assessed in sputum samples (r = 0.71; P b 0.01). Conclusions: YKL-40 is elevated in CF patients and is further elevated during severe exacerbations. Longitudinal studies in infant are needed to establish its role in disease pathogenesis.
2016
File in questo prodotto:
File Dimensione Formato  
3090992.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 251.57 kB
Formato Adobe PDF
251.57 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3090992
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 22
social impact